次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

医薬品受託製造サービス(CMO)の世界市場2015-2025年

PHARMACEUTICAL CONTRACT MANUFACTURING: WORLD INDUSTRY AND MARKET OUTLOOK 2015-2025

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年2月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文216ページになります。
商品コード:VGN371

※当レポートは更新版(2016版)が発行されております。更新版は下記リンクよりご参照ください
LinkIcon医薬品受託製造サービス(CMO)の世界市場2016-2026年

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】VGN371_Pharma CMO2025_thumbnail.jpg
医薬品受託製造サービス(CMO)の世界市場規模は、2013年時点の545億ドル規模から2019年には792億4000万ドルに達すると予測され、2025年にかけて力強い拡大基調にあります。当レポートでは、同世界市場予測(2015-2025)、セグメント別市場予測、主要国別市場予測、リーディング企業動向、市場の動向詳細分析、専門家オピニオンインタビューなどを織り交ぜ、概略以下の構成でお届けいたします。

【レポート構成概要】
・医薬品受託製造サービス(CMO)の世界市場予測2015-2025
・全216ページ、77個のデータ表、57個のチャート

・セグメント別市場予測2015-25
医薬品有効成分(API)
- ジェネリックAPI
- 高薬理活性API
- その他
最終製剤(FDF)
- 固形投与製剤
- 注射製剤
- その他製剤
委託製造その他製品
臨床製造(Clinical Manufacturing)
商業生産(Commercial Manufacturing)

・主要12ヶ国・地域別市場予測2015-25
- 米国
- EU地域
- ドイツ、フランス、英国、イタリア、スペイン
- ブラジル、ロシア、インド、中国
- 日本
- 韓国

・市場動向(諸論点)
- バイオ医薬品製造への投資トレンド
- 米国とEU規制、その他諸国における要件
- 後発品ユーザーフィー法(Generic Drug User Fee Act=GDUFA)とAPI製造
- 製剤開発サービスへの需要
- GMP基準(Good Manufacturing Practice)、設計による品質保証(Quality by Design: QbD)
- バーチャル製薬企業
- CMOにおけるマイクロリアクターの可能性
- ジェネリックベンダーの後方統合
- HPAPI製造施設への投資
- 希少疾病用医薬品、生物製剤やバイオシミラーの製造
- ソフトジェル製剤への需要と連続製造へのシフト
- 医薬品受託製造におけるグリーンテクノロジー
- 生物製剤と低分子医薬品の無菌充填
- 抗体コンジュケート(ADC)と新規たんぱく質の開発
- 凍結乾燥、噴霧乾燥、熱溶融押出、フィルフィニッシュ等のサービス

・リーディング企業プロフィール、業績、能力、展望
- Catalent Pharma Solutions
- Lonza
- Evonik Degussa
- Royal DSM
- Teva API.
(その他Boehringer BioXcellence、Vetter Pharma-Fertigung、Patheon、Famar、 Farevaなど)

・専門家オピニオンインタビュー:
- Dr Cynthia Wooge, Global Strategic Marketing Manager, SAFC
- Mr. Peter Soelkner, Managing Director of Vetter Pharma International GmbH

・調査結論

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

PHARMACEUTICAL CONTRACT MANUFACTURING: WORLD INDUSTRY AND MARKET OUTLOOK 2015-2025

Table of Contents

1. Report Overview

1.1 Pharma Contract Manufacturing: World Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Pharma Contract Manufacturing

2.1 An Introduction to Pharma Contract Manufacturing
2.1.1 Why Outsource in the Pharma Industry?
2.1.2 Services Offered by CMOs
2.1.3 Tactical and Strategic Manufacturing Outsourcing
2.1.4 Trends in Contract Manufacturing 2015-2025

3. The Pharma Contract Manufacturing Market: Outlook and Forecast 2015-2025

3.1 The Pharma Contract Manufacturing: Market Performance 2012-2013
3.1.1 Contract Manufacturing Is the Most Mature Pharma Outsourcing Sector
3.1.2 The Pharma Contract Manufacturing Market by Sector 2013
3.2 Pharma Contract Manufacturing: Overall Market Forecast 2015-2025
3.2.1 What Will Drive Growth for Contract Manufacturers 2015-2025?
3.2.2 Will Generics Drive or Restrain Market Growth?
3.2.3 Outlook and Revenue Forecast for Other Contract Manufacturing Services 2015-2025
3.2.3.1 Rising Demand for Formulation Development Services
3.3 Clinical and Commercial Manufacturing Services
3.3.1 Clinical-Stage Manufacturing: Submarket Forecast 2015-2025
3.3.2 Commercial-Stage Manufacturing: Submarket Forecast 2015-2025
3.4 Leading Contract Manufacturing Organisations (CMOs)
3.4.1 Catalent Pharma Solutions: The Market Leader
3.4.1.1 Expanding in Clinical and Biopharma Manufacturing
3.4.2 Lonza: An Expert in Biopharma Manufacturing
3.4.2.1 Lonza and Advanced Biopharma Manufacturing
3.4.3 Evonik Degussa: A Small Molecule Specialist
3.4.3.1 Growth in HPAPI Manufacturing
3.4.4 Royal DSM
3.4.4.1 Adding Biopharma Capacity
3.4.5 Teva API: The World’s Largest API Manufacturer
3.4.5.1 Will Teva Expand in Emerging Markets?
3.4.6 Patheon
3.4.6.1 Patheon Is Adding New Formulation Development Services
3.4.7 Boehringer BioXcellence: Boehringer’s Biopharma Manufacturing Division
3.4.7.1 Adding New Services for Growth
3.4.8 Famar
3.4.9 Fareva
3.4.10 Vetter Pharma: Aseptic Filling for Biologics and Small Molecules
3.4.10.1 Vetter Offers its Clients New Services

4. The Contract API Manufacturing Submarket: Outlook 2015-2025

4.1 The Contract API Manufacturing Submarket 2013
4.1.1 The API Manufacturing Submarket by Sector 2013
4.2 The Contract API Manufacturing Submarket Outlook 2014-2025
4.2.1 The Contract API Manufacturing Submarket Forecast 2015-2025
4.2.2 What Will Drive Submarket Growth to 2025?
4.2.2.1 The Potential for Microreactors in Commercial Manufacturing to 2025
4.2.3 How Will New EU Regulations Impact the API Manufacturing Submarket?
4.2.4 Contract API Manufacturing Submarket Restraints 2015-2025
4.2.4.1 Backwards Integration for Generics Manufacturers
4.3 The Contract Generic API Manufacturing Submarket 2015-2025
4.3.1 The Contract Generic API Manufacturing Submarket Forecast 2015-2025
4.3.2 The Contract Generic API Manufacturing Submarket Drivers and Restraints to 2025
4.3.2.1 The US Generic Drug User Fee Act and API Manufacturing
4.4 The Contract HPAPI Manufacturing Submarket 2015-2025
4.4.1 Challenges and Opportunities in High Containment Manufacturing
4.4.2 Many Companies Are Investing in HPAPI Manufacturing Facilities
4.4.3 The Contract HPAPI Manufacturing Submarket Forecast 2015-2025
4.4.4 Submarket Drivers and Restraints 2015-2025

5. The Contract FDF Manufacturing Submarket Outlook 2015-2025

5.1 The Contract FDF Manufacturing Submarket 2013
5.1.1 Solid Dosage Manufacturing Leads the Market
5.1.2 CMOs Report High Demand for Softgel Formulations
5.2 The Contract FDF Manufacturing Submarket Forecast 2015-2025
5.2.1 Complex Molecule Manufacturing Will Drive Growth to 2025
5.2.2 What Will Restrain Growth in FDF Outsourcing?
5.3 The Contract Solid Dosage Manufacturing Submarket 2015-2025
5.3.1 How Will Revenues for Solid Dosage Manufacturing Grow 2015-2025?
5.3.2 Submarket Drivers and Restraints 2015-2025
5.3.2.1 Will Product Reformulation Drive Growth to 2025?
5.4 The Contract Injectable Dosage Manufacturing Submarket 2015-2025
5.4.1 The Contract Injectable Dosage Manufacturing Submarket Forecast 2015-2025
5.4.1.1 Drug Shortages Offer an Opportunity for CMOs in the Short Term
5.4.2 Demand for Biopharma Manufacturing Will Drive Growth 2015-2025
5.4.2.1 Interest in Antibody Drug Conjugate Development Is Growing
5.4.2.2 Challenges in Manufacturing Antibody Drug Conjugates
5.4.3 Lyophilisation and Aseptic Filling Demand Will Rise
5.4.3.1 Will Spray Drying Replace Lyophilisation in FDF Manufacturing?

6. Pharma Contract Manufacturing: Leading Developed National Markets 2015-2025

6.1 Leading National Markets for Pharma Contract Manufacturing 2013
6.1.1 Challenges in Assessing the Market: Supply vs. Demand
6.1.2 Leading National Pharma Contract Manufacturing Markets: Revenue Forecasts 2015-2025
6.2 The US Is the Leading National Market in Terms of Demand
6.2.1 Pharma Manufacturing in the US: Regulatory Oversight 2013
6.2.1.1 Controlling Foreign Manufacturing Sites
6.2.1.2 What Impact Will the GDUFA 2012 Have on Foreign Manufacturing?
6.2.1.3 Outsourcing and US Manufacturing Regulations
6.2.2 Increased Demand for Domestic API Manufacturing?
6.2.3 The US Contract Manufacturing Submarket Forecast 2015-2025
6.3 Outlook for Pharma Contract Manufacturing in the EU
6.3.1 The EU is the Leading Destination for Pharma Contract Manufacturing
6.3.2 Regulatory Aspects to Pharma Manufacturing in the EU
6.3.2.1 The European Commission Amends Annex 16
6.3.2.2 The Falsified Medicine Directive: Controlling API Imports
6.3.3 Biopharma Manufacturing Demand Will Rise to 2025
6.3.4 The EU Contract Manufacturing Submarket Forecast 2015-2025
6.3.5 Germany: The Leading EU Destination for API and FDF Manufacturing
6.3.5.1 Demand for Contract Manufacturing in Germany: Revenue Forecast 2015-2025
6.3.6 CMOs Account for a Third of Manufacturing Sites in France
6.3.6.1 French Pharma Contract Manufacturing Submarket Forecast 2015-2025
6.3.7 Italy: Strong API Manufacturing Traditions
6.3.7.1 Revenue Forecast for the Italian Pharma Contract Manufacturing Submarket 2015-2025
6.3.8 Spain: How Will Demand for Manufacturing Services Grow to 2025?
6.3.9 The UK: Pharma Contract Manufacturing Submarket Forecast 2015-2025
6.4 Pharma Contract Manufacturing in Japan 2015-2025
6.4.1 Pharma Manufacturing Regulations in Japan
6.4.1.1 The Pharmaceutical Affairs Law
6.4.2 Greater API Outsourcing to Drive Japanese Submarket Growth to 2025

7. Pharma Contract Manufacturing: Leading Emerging National Markets 2015-2025

7.1 Pharma Contract Manufacturing in Developing Countries
7.1.1 Outsourcing to Emerging National Markets from Developed Markets
7.1.1.1 Demand for Services in India and China
7.1.2 Domestic Demand for Pharma Contract Manufacturing Services
7.1.3 Pharma Contract Manufacturing: Leading Emerging National Market Forecasts 2015-2025
7.2 Chinese Demand for Pharma Contract Manufacturing Services 2015-2025
7.2.1 Improved Manufacturing Regulations in China
7.2.1.1 New Regulations for Excipients and Guidance for API Manufacturing 2012-2013
7.2.1.2 What Are the Consequences to Stricter Manufacturing Regulations in China?
7.2.2 Chinese CMOs Are Investing in Biopharma Manufacturing
7.2.3 China Pharma Contract Manufacturing Submarket Forecast 2015-2025
7.3 India: CMOs with Growing Formulation Experience
7.3.1 Regulatory Outlook for Indian Pharma Manufacturing
7.3.1.1 Ensuring Compliance with New Rules in the EU
7.3.2 Domestic Manufacturing Dominates the Indian Pharma Market
7.3.3 Demand for Contract Manufacturing in India: Submarket Forecast 2015-2025
7.4 Brazil: Contract Manufacturing Outlook 2013-2025
7.4.1 Pharma Manufacturing Regulations in Brazil
7.4.1.1 New Guidelines and Regulations Proposed 2012-2013
7.4.2 Brazil Imports Most of its APIs
7.4.3 Brazil: Pharma Contract Manufacturing Submarket Forecast 2015-2025
7.5 The Russian Pharma Contract Manufacturing Submarket 2015-2025
7.5.1 Pharma Manufacturing Regulations in Russia
7.5.1.1 Compliance with GMP in Russia
7.5.2 How Will Demand for Contract Manufacturing Grow in Russia 2015-2025?
7.6 South Korea
7.6.1 South Korea: Strict GMP Regulations
7.6.2 South Korea: Pharma Contract Manufacturing Submarket Forecast 2015-2025

8. Pharma Contract Manufacturing Industry Trends: CMO Perspective 2015-2025

8.1 Pharma Contract Manufacturing Market: Strengths and Weaknesses for CMOs 2013-2014
8.2 Pharma Contract Manufacturing Market: Opportunities and Threats for CMOs 2015-2025
8.3 Pharma Contract Manufacturing Market: STEP Analysis 2015-2025
8.3.1 Social Factors
8.3.2 New Technologies Will Drive Market Growth to 2025
8.3.2.1 Single-Use Technologies in Biopharma Manufacturing
8.3.2.2 Green Technology in Contract Manufacturing
8.3.2.3 Drug Delivery Trends and CMOs
8.3.2.4 Biologics Are Causing Increased Demand for Lyophilisation
8.3.2.5 Improving Solubility and Stability for Small Molecules
8.3.2.6 Spray Drying as an Alternative to Lyophilisation
8.3.2.7 Hot-Melt Extrusion
8.3.3 Economic Pressures
8.3.3.1 Developed-Market CMOs Face Competition from Emerging Markets
8.3.4 Political Issues
8.3.4.1 How Will Regulatory Developments Affect CMOs?
8.4 Trends in Drug Development Affecting CMOs to 2025
8.4.1 Orphan Drug Development: Smaller Manufacturing Capacities
8.4.2 Complex Biologics: Interest in ADCs is Rising
8.4.3 How Will Biosimilar Market Growth Affect CMOs?
8.4.4 The Future of Small Molecule Outsourcing
8.5 How Will CMOs Expand in the Coming 10 Years?
8.5.1 CMO Consolidation Will Increase
8.5.2 There Will be More Manufacturing Facilities Available for Acquisition
8.6 Developments in the Manufacturing Process 2015-2025
8.6.1 Quality by Design (QbD)
8.6.2 A Move Towards Continuous Manufacturing?

9. Pharma Contract Manufacturing Industry Trends: Client Perspective 2015-2025

9.1 Pharma Contract Manufacturing: Client Perspective Industry Strengths and Weaknesses 2013-2014
9.2 Pharma Contract Manufacturing: Client Perspective Industry Opportunities and Threats 2015-2025
9.3 Important Aspects of the Outsourcing Decision
9.3.1 What Factors Will Influence CMO Selection?
9.3.2 CMO-Pharma Partnering Models
9.3.3 Strategic Partnering
9.3.4 Selecting a Local CMO vs. Offshoring
9.3.5 CMOs in Emerging Markets
9.3.6 Communication
9.3.7 Ensuring Protection in Intellectual Property and Tech Transfer
9.3.8 Regulatory Compliance is a Key Deciding Factor for Pharma Clients
9.3.8.1 Regulatory Bodies and Outsourcing
9.3.8.2 Quality Agreement
9.3.8.3 Global Harmonisation Will Improve Compliance
9.4 Trends in Outsourcing Partnerships 2015-2025
9.4.1 Big Pharma and Outsourced Manufacturing
9.4.2 Small and Virtual Pharma Companies
9.4.3 How Will Biotech Funding Affect the Pharma Contract Manufacturing Industry to 2025?

10. Research Interviews from Our Industry Survey

10.1 Dr Cynthia Wooge, Global Strategic Marketing Manager, SAFC
10.1.1 SAFC
10.1.2 Are ADCs Limited to Oncology?
10.1.3 The Challenges of ADCs Manufacturing
10.1.4 What Solution Does SAFC Offer for ADCs Manufacturing?
10.1.5 Advancement in Conjugation Technology
10.2 Mr. Peter Soelkner, Managing Director of Vetter Pharma International GmbH
10.2.1 Vetter
10.2.2 Singapore, a Global Biomedical Sciences Hub
10.2.3 Market Outlook for APAC Region
10.2.4 Challenges to Be Addressed in the APAC Region

11. Conclusions of the Study

11.1 The World Pharma Contract Manufacturing Market
11.2 Outlook for the Market to 2025
11.2.1 Rising Demand for High Value Services 2015-2025
11.2.2 Demand Will be Highest Among Developed Market Clients
11.3 Which New Technologies Will Stimulate Demand to 2025?

List of Tables

Table 1.1 Pharmaceutical Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2025
Table 1.2 Currency Exchange Rates
Table 3.1 Pharma Contract Manufacturing Market Revenue ($bn), 2012-2013
Table 3.2 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2013
Table 3.3 Pharma Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2025
Table 3.4 Pharma Contract Manufacturing Market: Submarket Shares (%), 2014-2025
Table 3.5 Other Services Submarket Forecast ($bn), 2015-2025
Table 3.6 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Development Stage, 2013
Table 3.7 Clinical Manufacturing Submarket Forecast ($bn), 2015-2025
Table 3.8 Commercial Manufacturing Submarket Forecast ($bn), 2015-2025
Table 3.9 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Top Company, 2013
Table 3.10 Catalent: Revenue ($bn), 2009-2014
Table 3.11 Lonza Custom Manufacturing: Revenue ($bn), 2009-2013
Table 3.12 DSM Pharmaceutical Products: Revenue ($bn), 2009-2013
Table 3.13 Teva API: Revenue ($bn), 2009-2013
Table 3.14 Patheon: Revenue ($bn), 2009-2013
Table 3.15 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2013
Table 3.16 Famar: Revenue ($bn), 2009-2013
Table 4.1 Contract API Manufacturing Submarket Revenue ($bn), 2012-2013
Table 4.2 Contract API Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2013
Table 4.3 Contract API Manufacturing Submarket: Overall Submarket and Revenue Forecasts by Sector ($bn), 2015-2025
Table 4.4 Contract API Manufacturing Submarket: Submarket Shares (%), 2014-2025
Table 4.5 Contract API Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 4.6 Contract Generic API Manufacturing Submarket Forecast ($bn), 2015-2025
Table 4.7 Contract Generic API Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 4.8 Contract HPAPI Manufacturing Submarket Forecast ($bn), 2015-2025
Table 4.9 Contract HPAPI Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.1 Contract FDF Manufacturing Submarket Revenue ($bn), 2012-2013
Table 5.2 Contract FDF Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2013
Table 5.3 Contract FDF Manufacturing Submarket: Overall Submarket and Revenue Forecasts by Sector ($bn), 2015-2025
Table 5.4 Contract FDF Manufacturing Submarket: Segment Shares (%), 2014-2025
Table 5.5 Contract FDF Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.6 Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Table 5.7 Contract Solid Dosage Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.8 Contract Injectable Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Table 5.9 Contract Injectable Dosage Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.10 ADCs in Phase II and III Development, 2013
Table 5.11 Selected CMOs Investing in ADC Manufacturing Capacity, 2014
Table 6.1 Pharma Contract Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2013
Table 6.2 Pharma Contract Manufacturing Market: Regional Revenue Forecasts ($bn), 2015-2025
Table 6.3 Pharma Contract Manufacturing Market: Developed Market Submarket Shares (%), 2014-2018
Table 6.3 (Cont’d) Pharma Contract Manufacturing Market: Developed Market Submarket Shares (%), 2019-2025
Table 6.4 GDUFA: Annual Fees for Domestic and Foreign Manufacturing Sites, 2014-2015
Table 6.5 US Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.6 EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2013
Table 6.7 Catalent: Revenue ($bn) and Assets (%) by Region, 2013
Table 6.8 EU5 Pharma Contract Manufacturing Market: National Submarket Forecasts ($bn), 2015-2025
Table 6.8 (Cont’d) EU Pharma Contract Manufacturing Market: National Submarket Forecasts ($bn), 2015-2025
Table 6.9 German Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.10 Selected French Manufacturing Site Acquisitions, 2009-2013
Table 6.11 French Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.12 Italian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.13 Spanish Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.14 UK Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.15 Japanese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.1 Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2013
Table 7.2 Pharma Contract Manufacturing Market: Leading Emerging Market Submarket Forecasts ($bn), 2015-2025
Table 7.3 Pharma Contract Manufacturing Market: Emerging Market Submarket Shares (%), 2014-2025
Table 7.3 (Cont’d) Pharma Contract Manufacturing Market: Emerging Market Submarket Shares (%), 2014-2025
Table 7.4 Chinese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.5 Indian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.6 Brazilian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.7 Russian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.8 South Korean Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 8.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2015-2025
Table 8.2 Pharma Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2015-2025
Table 8.3 Pharma Contract Manufacturing Market: STEP Analysis, 2015-2025
Table 8.4 Selected Lyophilisation Service Providers, 2014
Table 8.5 Lyophilisation vs. Spray Drying: A Comparison
Table 8.6 Selected Orphan Drug Prices, 2013
Table 8.7 Biological Manufacturing Expansion, 2011-2013
Table 8.8 Selected CMOs Growing Faster than the Market, 2007-2012
Table 8.9 Regional Market Expansion, 2010-2013
Table 9.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2015-2025
Table 9.2 Pharma Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2015-2025
Table 9.3 Benefits and Risks to Outsourcing Pharma Manufacturing, 2015
Table 9.4 ICH Guidelines: Key Facts and Adoption, 2000-2012
Table 11.1 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2013, 2019 and 2025
Table 11.2 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Region, 2013, 2019 and 2025

List of Figures

Figure 2.1 Selected Services Offered by CMOs, 2015
Figure 2.2 Major Trends Affecting Pharma Contract Manufacturing Revenue Growth, 2015-2025
Figure 3.1 Pharma Contract Manufacturing Market Revenue ($bn), 2012-2013
Figure 3.2 Pharma Contract Manufacturing: Market Share (%) by Sector, 2013
Figure 3.3 Pharma Contract Manufacturing Market Forecast ($bn), 2015-2025
Figure 3.4 Pharma Contract Manufacturing Market: Submarket Shares (%), 2019
Figure 3.5 Pharma Contract Manufacturing Market: Submarket Shares (%), 2025
Figure 3.6 Pharma Contract Manufacturing Market: Drivers, 2015-2025
Figure 3.7 Pharma Contract Manufacturing Market: Restraints, 2015-2025
Figure 3.8 Other Services Submarket Forecast ($bn), 2015-2025
Figure 3.9 Pharma Contract Manufacturing: Market Share (%) by Developmental Stage, 2013
Figure 3.10 Clinical Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 3.11 Commercial Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 3.12 Pharma Contract Manufacturing: Market Share (%) by Top Company, 2013
Figure 3.13 Catalent: Revenue ($bn), 2009-2014
Figure 3.14 Lonza Custom Manufacturing: Revenue ($bn), 2009-2013
Figure 3.15 DSM Pharmaceutical Products: Revenue ($bn), 2009-2013
Figure 3.16 Teva API: Revenue ($bn), 2009-2013
Figure 3.17 Patheon: Revenue ($bn), 2009-2013
Figure 3.18 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2013
Figure 3.19 Famar: Revenue ($bn), 2009-2013
Figure 4.1 Contract API Manufacturing Submarket Revenue ($bn), 2012-2013
Figure 4.2 Contract API Manufacturing Submarket: Submarket Share (%) by Sector, 2013
Figure 4.3 Contract API Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 4.4 Contract API Manufacturing Submarket: Submarket Shares (%), 2019
Figure 4.5 Contract API Manufacturing Submarket: Submarket Shares (%), 2025
Figure 4.6 Contract Generic API Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 4.7 Contract HPAPI Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 5.1 Contract FDF Manufacturing Submarket Revenue ($bn), 2012-2013
Figure 5.2 Contract FDF Manufacturing Submarket: Submarket Share (%) by Sector, 2013
Figure 5.3 Contract FDF Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 5.4 Contract FDF Manufacturing Submarket: Submarket Shares (%), 2019
Figure 5.5 Contract FDF Manufacturing Submarket: Submarket Shares (%), 2025
Figure 5.6 Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 5.7 Contract Injectable Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 6.1 Pharma Contract Manufacturing Market: Share (%) by Region, 2013
Figure 6.2 Pharma Contract Manufacturing Market: Share (%) by Region, 2019
Figure 6.3 Pharma Contract Manufacturing Market: Share (%) by Region, 2025
Figure 6.4 US Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.5 EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2013
Figure 6.6 EU5 Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.7 German Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.8 French Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.9 Italian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.10 Spanish Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.11 UK Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.12 Japanese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.1 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2013
Figure 7.2 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2013, 2019 and 2025
Figure 7.3 Chinese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.4 Indian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.5 Brazilian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.6 Russian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.7 South Korean Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 9.1 Overview of ICH Manufacturing Guidelines, 2013
Figure 11.1 Pharma Contract Manufacturing Market: Revenue ($bn) by Sector, 2013, 2019 and 2025
Figure 11.2 Pharma Contract Manufacturing Market: Revenue ($bn) by Region, 2013, 2019 and 2025

掲載企業リスト

Companies Listed

AbbVie
Actavis
Aegerion Pharmaceuticals
Aenova Group
Aesica Pharma
Agência Nacional de Vigilância Sanitária (ANVISA)
Alexion Pharmaceuticals
Almac Group
Althea Technologies
AMRI
Aneona Group
Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
Aspen Pharmacare
Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
Association of British Pharmaceutical Industry (ABPI)
AstraZeneca
Banner Pharmacaps
Barring Private Equity Asia
Bausch & Lomb
Bayer
Ben Venue Laboratories
Bend Research
Biogen Idec
BioIndustry Association (BIA)
Biotest
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence
Bristol-Myers Squibb Company
Bushu Pharmaceuticals
Cambrex
Cambridge Major Laboratories
Carbogen Amcis
Catalent Pharma Solutions
Cedarburg Hauser
Cell Therapy Catapult
Celladon Corporation
Celldex
Celltrion
Cenexi
Central Drugs Standard Control Organization (CDSCO)
Chemisch-Pharmazeutisches Laboratorium Ravensburg
Chemtrix
China FDA (CFDA)
Cipla
Cook Pharmica
CTC Bio
Daito Pharmaceutical
Delpharm
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
Dishman Pharmaceuticals
DPx Holdings B.V.
Dr. Reddy’s Laboratories
Eisai
Eli Lilly
Esteve Quimica
European Commission
European Medicines Agency (EMA)
Euticals
Evonik Degussa
Famar
Fareva
Food and Drug Administration (US FDA)
FUJIFILM Diosynth Biotechnologies,
Gallus Biopharamceutical, LLC.
G-CON
GEA Pharma-Systems
Genentech
GlaxoSmithKline (GSK)
Granules India
Haupt Pharma
Hexal
Hospira
Hospira One2One
Immunogen
Immunomedics
Indian Drug Manufacturer’s Association (IDMA)
Indian Pharmaceutical Alliance
Innovent Biologics
International Society of Pharmaceutical Engineering (IPSE)
Janssen
JK Pharmaceutical
Knowledge Transfer Network (KTN)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer’s Association (KPMA)
Lonza
Lupin
Marinopoulos Group
Matrix Laboratories
Medice
Medichem
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Merck & Co.
Micron Technologies
Millenium
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Industry and Information Technology (MIIT)
Mitsui & Co.
Mylan
NPS Pharmaceuticals
Nycomed
Orchid Chemicals & Pharmaceuticals
Oxford Biomedica
Patheon
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacyclics
Piramal Pharma Solutions
Progenics
Quintiles
Recepta Biopharma
Recipharm
Redwood Bioscience
Rentschler Biotechnologie
Roche
ROVI
Royal DSM
SAFC
SafeBridge
Samsung BioLogics
Sandoz
Sanofi
Seattle Genetics
SELLAS Life Sciences Group
Shandong Xinhua
ShangPharma
Shire
Siegfried
Sigmar Italia
Sinochem
SMS Pharmaceuticals
Stada
Stem CentRx
Stevenage Bioscience Catalyst
Takeda
Teva API
Thermo Fisher Scientific
UMN Pharma
UNIGEN
Valeant Pharmaceuticals
Valerion Therapeutics, LLC.
Vetter Pharma-Fertigung GmbH
Vivante GMP Solutions
West Pharmaceutical Services
World Health Organization (WHO)
WuXi PharmaTech
Zhangjiang Biotech & Pharmaceutical Base Company
Zhejiang Jiang Yuan Tang Biotechnology

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

関連レポート紹介

LinkIcon医薬品受託製造サービス(CMO)のリーディング企業2014-2024年

特に生物製剤とバイオシミラーは成長分野であるほか、薬剤結合抗体、高活性API(原薬)や再生医療といった新たな治療法にも業界の期待が集まっています。

LinkIconワクチン製造技術と受託製造サービスの世界市場2014-2024年

ワクチン受託製造サービスの世界市場は2014年に7億562万ドルに達すると推計され、2014年から2024年にかけて力強い成長が見込まれます。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。